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BRIEF COMMUNICATION
Epidemiology
Body mass index and Hodgkin's lymphoma: UK population-
based cohort study of 5.8 million individuals
Helen Strongman1, Adam Brown1, Liam Smeeth1 and Krishnan Bhaskaran1
Previous epidemiological studies describe a positive association between body mass index (BMI) and Hodgkin’s lymphoma, mainly
in obese vs. normal weight individuals. We examined the shape of this relationship in individuals aged 16 years or older, using
primary care data from the United Kingdom’s Clinical Practice Research Datalink. Cox models were ﬁtted with linear, non-linear
(spline) and categorical BMI. Models were adjusted for potential confounders and effect modiﬁcation was investigated. Five point
eight two million patients were included, 927 of whom developed Hodgkin’s lymphoma during 41.6 million years of follow-up. Each
5 kg/m2 increase in BMI was associated with a 10% increase in Hodgkin’s lymphoma (95% conﬁdence intervals: 2–19). Analysis of
non-linearity suggested a J-shaped association with incidence increasing with BMI above 24.2 kg/m2. Seven point four per cent
of adult Hodgkin’s lymphoma cases were estimated to be attributable to excess weight. Our ﬁndings suggest a pattern of
increasing risk beyond the World Health Organisation healthy weight category in the general population.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0401-1
INTRODUCTION
Obesity can modify immune function and thus may increase risk
of Hodgkin's lymphoma (HL).1 Evidence suggests a positive
association between body mass index (BMI) and HL, but there
have been few studies, and limited investigation into the shape of
the relationship. Our group has previously characterised associa-
tions between BMI and 22 common cancers.2 We have extended
this work to test the association between BMI and incident HL
using the same methodology and population-based primary care
database (Clinical Practice Research Datalink (CPRD) GOLD) to the
previous study.2
METHODS
The CPRD GOLD database includes information collected during
primary care consultations in the United Kingdom (UK) National
Health Service to inform future clinical care. This includes BMI
measurements collected following registration with the current or
former practice, or during medical visits, either opportunistically or
to inform speciﬁc medical decisions.3 Variables indicating the start
of patient registration at the CPRD practice and start of continuous
recording of data at the practice are used to deﬁne the start of
research quality follow-up. We included individuals in CPRD aged
16 years or older with any BMI measurement recorded, eligible
research quality follow-up time and no previous cancer diagnosis.
BMI was calculated directly from height and weight records
(weight/height2). If BMI was recorded at the start of research
quality follow-up, study follow-up started 12 months after the ﬁrst
BMI measurement to avoid reverse causality. If not, follow-up
started 12 months after the start of registration and the most
recent previous BMI (if available) was used. This was time updated
when the ﬁrst research standard BMI was recorded. Outcomes
were ascertained using clinical codes indicating malignant HL
diagnosis. Follow-up ended at lymphoma diagnosis or end of
patient or practice data collection.
We assessed linear and non-linear (restricted cubic spline)
associations of BMI with HL. Cox proportional hazards models with
attained age as the underlying time-scale were adjusted for
covariates at ﬁrst BMI measurement: age (restricted cubic spline),
smoking status, alcohol use, previous diabetes diagnosis, index of
multiple deprivation, calendar period; stratiﬁed by sex. Patients
with missing data for smoking or alcohol status were removed.
Effect modiﬁcation by sex, age (time updated) and smoking status
was investigated using interaction terms and restriction to non-
smokers. The proportional hazards assumption was investigated
using Schoenfeld residuals. The population attributable fraction
was calculated by ﬁtting a three-category BMI variable (BMI < 18.5,
18.5–25, ≥25 kg/m2), and combining estimated hazard ratios (HRs)
for overweight and obesity with national prevalence (Health
Survey for England 2010). The results of Cox proportional hazards
models with BMI measured in World Health Organisation (WHO)
categories are also reported to allow for comparison with previous
publications. The study was approved by the London School of
Hygiene and Tropical Medicine Ethics Committee and the pre-
speciﬁed scientiﬁc protocol was approved by the Independent
Scientiﬁc Advisory Committee for MHRA Database Research
(protocol 12_090A3).
RESULTS
The initial study population included 6.33 million individuals aged
16 years or older in CPRD, with eligible follow-up time and no
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cancer diagnosis before cohort entry. These individuals had a
mean ﬁrst BMI of 25.6 kg/m2 (SD 5.2); 3.45 million (54.5%) subjects
were female. People in higher BMI categories were older (median
age 42.7 years among overweight/obese individuals vs. 37.4
among healthy weight individuals), less likely to be current
smokers (overweight/obese: 32.1% vs. healthy weight: 36.2%), and
more likely to have had a diabetes diagnosis (overweight/obese:
5.0%; healthy weight: 1.6%). Mean duration of follow-up was 8.9
years (SD 6.5) from the ﬁrst BMI record. There were some missing
data for smoking status (0.8%) and alcohol use (7.9%).
Of 5.82 million patients with complete data, 927 developed HL
during 41.6 million years of follow-up. Each 5 kg/m2 linear increase
in BMI was associated with the same estimated 10% increase in HL
in crude and adjusted models (hazard ratio (HR) 1.10, 99%
conﬁdence interval (CI): 1.02–1.19) providing strong evidence of a
positive association between BMI and incident HL.
Figure 1 shows the estimated shape of the BMI–HL association
using ﬂexible spline models. The association appears to be J-
shaped with HL risk increasing above 24.3 kg/m2. There was
strong evidence of association (p < 0.001) and a suggestion of
non-linearity (p= 0.06). We found no evidence of effect modiﬁca-
tion by sex, age or smoking status, and no evidence against the
proportional hazards assumption (p= 0.37). Crude and adjusted
models with BMI represented in WHO categories provide weak
evidence of an association with obesity (adjusted HR 1.19, 99% CI:
0.94–1.50) and no evidence of an association with overweight
(adjusted HR 0.99, 99% CI: 0.81–1.21). Under the assumption of
causality, we estimated that 7.4% of HL cases were attributed to
overweight and obesity.
DISCUSSION
We found strong evidence of a positive association between BMI
and incident HL, with an estimated 10% increase in HL risk per 5
kg/m2 increase in BMI (95% CI: 2–19); however, analysis allowing
for non-linearity was suggestive of a J-shaped relationship, with
positive associations only at BMIs above 24.2 kg/m2. Seven point
four per cent of adult HL cases were estimated to be attributable
to excess weight.
The direction of effect and evidence of non-linearity is
consistent with previous studies. However, the effect size is
considerably smaller. The recent UK Million Women study
indicated a 64% increased risk per 10 kg/m2 increase (95% CI:
21–221)4 which is equivalent to a 28% increased risk per 5 kg/m2
increase (95% CI: 10–49). An earlier meta-analysis of ﬁve studies5
found strong evidence of a higher risk in obese vs. normal weight
individuals (relative risk (RR) 1.41, 95% CI: 1.14–1.75), but no
evidence of a higher risk in the overweight category (RR 0.97, 95%
CI: 0.85–1.12).
CPRD GOLD is a large data source that has been shown to have
a high level of validity generally,3 and speciﬁcally for cancers6 and
recently recorded BMI measurements.7 Analysing non-linear
effects using a spline model allowed a more nuanced picture to
emerge than using BMI categories alone and was suggestive of a
gradual increase in risk of HL from 24.3 kg/m2 rather than the
absence of effect in the overweight category (25 to ≤30 kg/m2).
The study also has important limitations. Our study population
was restricted to individuals who had BMI, smoking and alcohol
status measured in their primary care practice. This would
introduce selection bias if the association of BMI, HL and
confounders varied between patients with measured and
unmeasured BMI, smoking and alcohol status. Previous research
and multiple sensitivity analyses in our multi-cancer analysis left
us conﬁdent that this did not cause major bias.2,7 There is also the
potential for residual confounding due to unmeasured confoun-
ders. These include amount smoked, physical exercise, ethnicity
and potential confounders that are speciﬁc to HL, for example,
Epstein–Barr virus.8 Published analyses to date have used BMI data
collected for research purposes,4,9–11 as part of a mandatory
medical examination for a national insurance scheme,12 or during
a compulsory national screening programme.13 Cancer outcomes
have primarily been ascertained using cancer registry data. These
studies have a similar potential for selection bias or residual
confounding, although there are differences in the purpose and
therefore completeness of BMI data collection and the availability
of data to measure potential confounders.
Inﬂammation is central to the pathology of HL and associated
with adiposity. The association between excess weight and HL may
therefore be regulated by the immunomodulatory effect of adipose
tissue.1 To test this theory, future epidemiological studies should
use more precise measures of whole and local body fatness.1
Studies could also investigate the impact of duration of obesity and
weight change on HL incidence. However, repeated BMI measures
and measures of adiposity other than BMI are not yet consistently
available in large, population-based databases. As population
coverage and completeness of data recording improves, it will
also be possible to investigate associations between adiposity and
measures of tumour aggressiveness or HL mortality by incorporat-
ing linked cancer registration and death data.
In conclusion, our analysis strengthens evidence of a pattern of
increased risk of HL with increasing BMI. This supports calls for
strategies to prevent excess weight gain beyond the WHO healthy
weight category in the general population. Large prospective
cohort studies with improved measures of body fat would help
elucidate the mechanisms through which adiposity affects HL risk.
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Fig. 1 Association between body mass index (BMI) and Hodgkin's
lymphoma (HL), allowing for non-linear effects, with 99% conﬁdence
intervals (CIs). The reference BMI (with HR ﬁxed as 1.0) was 22 kg/m2.
The model included a 3-knot restricted cubic spline for BMI (knots
placed at equal percentiles of BMI), adjusted for age (3-knot
restricted cubic spline), calendar year, diabetes status, alcohol use,
smoking, geographical area-based deprivation (index of multiple
deprivation), and stratiﬁed by sex. HR= hazard ratio
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